View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 9, 2020updated 04 Sep 2020 1:51pm

Russia approves R-Pharm’s Coronavir for Covid-19 treatment

Russian pharmaceutical company R-Pharm has secured regulatory approval for the use of its antiviral drug Coronavir, to treat patients suffering from Covid-19.

Russian pharmaceutical company R-Pharm has secured regulatory approval for the use of its antiviral drug Coronavir, to treat patients suffering from Covid-19.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

The approval comes after a clinical trial in mild to moderate Covid-19 patients showed that the drug is highly effective in blocking replication of SARS-CoV-2, the novel coronavirus that causes the disease.

R-Pharm was quoted by Reuters as saying: “Coronavir is one of the first drugs in Russia and in the world that does not tackle the complications caused by SARS-CoV-2, but battles the virus itself.”

Study data revealed improvement in 55% of outpatients on day seven of treatment with the drug, compared to 20% of those on standard etiotropic therapy, which targets disease cause instead of symptoms.

In addition, a significant difference was observed at 14 days, added the company. The virus was found to be eliminated in 77.5% of Covid-19 patients by day five of treatment with Coronavir.

In a statement, R-Pharm medical director Mikhail Samsonov said: “Global clinical practice and the clinical study we conducted have confirmed that Coronavir puts a much more rapid stop to the infection as a result of its effective obstruction of the virus’s replication.”

According to Russia’s Central Research Institute of Epidemiology clinical trials head Tatyana Ryzhentsova, the drug entered clinical testing in May and has been used to treat more than 110 outpatients so far.

Last month, Russia granted temporary approval to Covid-19 treatment, Avifavir, produced by the Russian Direct Investment Fund (RDIF) and ChemRar Group.

Said to be the country’s first Covid-19 drug, Avifavir is a generic version of anti-flu drug Avigan, used in Japan since 2014 to treat severe forms of influenza.

RDIF is now seeking approval for the use of the drug to treat Covid-19 at home, noted Reuters.

Avifavir yielded positive data in Phase II and III trials, as well as during the first month of hospital use in patients with early and middle stages of Covid-19.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU